HYPERTENSION IN CKD MARKET ANALYSIS

Hypertension in CKD Market, By Drug Class (Diuretics, RAS Blockade, β-Blockers, Calcium Channel Blockers, Others (α-Blockers, Vasodilators, Proteinuria, etc.) ), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Oct 2023
Code : CMI4431
Pages :135
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Global Hypertension in CKD Market – Key Players

Major players operating in the global hypertension in CKD market include Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG., C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd., KBPBiosciences Holdings Limited, Ardelyx, Reata Pharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd, Pfizer Inc., Bayer Pharmaceuticals, Inc, GSK plc.

Companies covered:

Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG., C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd., KBP Biosciences Holdings Limited, Ardelyx, Reata Pharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd, Pfizer Inc., Bayer Pharmaceuticals, Inc, GSK plc.